Why Autolus Therapeutics plc’s (AUTL) Stock Is Up 5.36%
As of Tuesday, July 21, Autolus Therapeutics plc’s AUTL share price has surged by 5.36%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Commentary & Analysis
Why Autolus Therapeutics plc’s (AUTL) Stock Is Down 5.03%
As of Friday, July 10, Autolus Therapeutics plc’s AUTL share price has dipped by 5.03%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Autolus Therapeutics plc’s (AUTL) Stock Is Up 7.72%
As of Tuesday, June 23, Autolus Therapeutics plc’s AUTL share price has surged by 7.72%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Autolus Therapeutics plc’s (AUTL) Stock Is Up 6.38%
As of Wednesday, June 17, Autolus Therapeutics plc’s AUTL share price has surged by 6.38%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Autolus Therapeutics plc’s (AUTL) Stock Is Down 5.56%
As of Monday, June 08, Autolus Therapeutics plc’s AUTL share price has dipped by 5.56%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | AUTL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $396.6 | $252.6 | 35% |
|
| Shares Out (Mil) | 266.1 | 52.3 | 81% |
|
| Institutional Ownership | 97.2% | 92.1% | 73% |
|
| Float (Mil) | 117.6 | 40.2 | 64% |
|
| Beta | 2.03 | 0.95 | 92% |
|
| Avg Daily Volume (000s) | 806 | 455 | 67% |
|
| Price Change (52-week) |
(40.2%) | 52.9% | 19% |
|
| Growth | AUTL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 113.5% | 13.6% | 99% |
|
| Net Income (5yr) | (15.1%) | (9.9%) | 25% |
|
| EPS (5yr) | 17.1% | 16.0% | 62 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 16.2% | (15.6%) | 75% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | na | 8 | |
| Current EPS | ($0.225) | na | ($0.887) | |
| Month Ago EPS | ($0.225) | na | ($0.885) | |
| # Rev Up | 1 | na | 0 | |
| # Rev Down | 0 | na | 1 | |
| Three Months Ago EPS | ($0.255) | na | ($0.928) | |
| Year/Year Chg | (16.4%) | na | na | |
| Financials | AUTL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $93 | $38 | 26% |
|
| Net Income (TTM) (Mil) | ($289) | ($43) | 5% |
|
| EPS (TTM) | ($1.086) | ($1.600) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($273) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $35 | $5 | 67% |
|
| Long-Term Debt (Q1) (Mil) | $354 | $5 | 55% |
|
| Enterprise Value (Q1) (Mil) | $542 | $180 | 35% |
|
| Valuation | AUTL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.63 | 2.56 | 70% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | AUTL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (125.1%) | 63.8% | 2% |
|
| Net Margin | (312.0%) | (67.3%) | 3% |
|
| ROA | (45.4%) | (49.8%) | 13% |
|
| ROE | (120.4%) | (55.5%) | 8% |
|
| Liabilities to Assets | 79.4% | 30.3% | 74% |
|
| F-Score | 1 | 3 | 1% |
|
Autolus Therapeutics plc did not pass any screens on 7/31/2026.
